Filing Flows › Comparisons › ZLAB vs XERS
Zai Lab vs Xeris Biopharma Holdings: ZLAB and XERS compared
Zai Lab is the larger company: $108M of revenue in its latest quarter (Q3 2026) against $107M for Xeris Biopharma Holdings (Q3 2026). Xeris Biopharma Holdings is growing faster (+44% against -7% a year earlier). Xeris Biopharma Holdings is more profitable, with an operating margin of 15.8% against -58.2%.
Where the money goes: ZLAB and XERS
Zai Lab (ZLAB) · Q3 2026
Zai Lab, Q3 2026: revenue $108M (-7% year over year), operating margin -58.2%, net loss $46.1M, operating cash flow −$57.9M. The chart follows the revenue to costs, profit and cash.
Xeris Biopharma Holdings (XERS) · Q3 2026
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
| Zai Lab (ZLAB) | Xeris Biopharma Holdings (XERS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $108M | $107M |
| Revenue growth, Y/Y | -7% | +44% |
| Operating margin | -58.2% | 15.8% |
| Net earnings | −$46.1M | $11.3M |
| Net margin | -42.6% | 10.5% |
| Operating cash flow | −$57.9M | $35.5M |
Where the revenue comes from
Zai Lab
- ZEJULA: $32.3M (30%)
- VYVGART / VYVGART Hytrulo: $24.1M (22%)
- NUZYRA: $21.1M (19%)
- QINLOCK: $8.8M (8%)
Xeris Biopharma Holdings
- Product revenue, net: $106M (99%)
- Royalty, contract and other revenue: $958K (1%)
Questions
Which is bigger, Zai Lab or Xeris Biopharma Holdings?
Zai Lab is the larger company: $108M of revenue in its latest quarter (Q3 2026) against $107M for Xeris Biopharma Holdings (Q3 2026).
Is Zai Lab or Xeris Biopharma Holdings growing faster?
Xeris Biopharma Holdings is growing faster (+44% against -7% a year earlier).
Which is more profitable, Zai Lab or Xeris Biopharma Holdings?
Xeris Biopharma Holdings is more profitable, with an operating margin of 15.8% against -58.2%.
More: Zai Lab earnings · how Zai Lab makes money · Xeris Biopharma Holdings earnings · how Xeris Biopharma Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.